-
中文名稱：人血小板因子4變體(PF4V1)酶聯免疫試劑盒
-
貨號：CSB-EL017810HU
-
規格：96T/48T
-
價格：￥3600/￥2500
-
其他：
產品詳情
-
產品描述：人血小板因子4變體(PF4V1)酶聯免疫試劑盒（CSB-EL017810HU）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織培養上清液、組織勻漿樣本中的PF4V1含量。PF4V1，也稱為CXCL4L1，是一種血小板相關趨化因子，具有抗血管生成功能，與炎癥、血管生成和癌癥有關。其研究機制涉及結構差異和功能特性，如與肝素結合能力較弱，以及作為血管生成抑制劑和內皮細胞趨化性抑制劑的作用。試劑盒檢測范圍為0.625 ng/mL-40 ng/mL，適用于體外科研場景，如探索PF4V1在疾病模型中的表達調控機制、評估藥物或基因干預對血小板活化的影響，或分析不同組織來源樣本中該因子的動態變化，為細胞信號通路研究及生物標志物篩選提供可靠工具。本品僅用于科研，不用于臨床診斷，產品具體參數及操作步驟詳見產品說明書。
-
別名：PF4V1 ELISA Kit; CXCL4V1 ELISA Kit; SCYB4V1 ELISA Kit; Platelet factor 4 variant ELISA Kit; C-X-C motif chemokine 4 variant ELISA Kit; CXCL4L1 ELISA Kit; PF4alt ELISA Kit; PF4var1) [Cleaved into: Platelet factor 4 variant(4-74); Platelet factor 4 variant(5-74); Platelet factor 4 variant(6-74)] ELISA Kit
-
縮寫：
-
Uniprot No.：
-
種屬：Homo sapiens (Human)
-
樣本類型：serum, plasma, cell culture supernates, tissue homogenates
-
檢測范圍：0.625 ng/mL-40 ng/mL
-
靈敏度：0.156 ng/mL
-
反應時間：1-5h
-
樣本體積：50-100ul
-
檢測波長：450 nm
-
研究領域：Others
-
測定原理：quantitative
-
測定方法：Sandwich
-
精密度：
Intra-assay Precision (Precision within an assay): CV%<8% Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV%<10% Three samples of known concentration were tested in twenty assays to assess. -
線性度：
To assess the linearity of the assay, samples were spiked with high concentrations of human PF4V1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. Sample Serum(n=4) 1:1 Average % 94 Range % 89-99 1:2 Average % 98 Range % 95-103 1:4 Average % 102 Range % 94-106 1:8 Average % 95 Range % 90-98 -
回收率：
The recovery of human PF4V1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. Sample Type Average % Recovery Range Serum (n=5) 92 89-95 EDTA plasma (n=4) 99 96-103 -
標準曲線：
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. 
ng/ml OD1 OD2 Average Corrected 40 2.945 3.094 3.020 2.831 20 2.266 2.399 2.333 2.144 10 1.532 1.497 1.515 1.326 5 0.775 0.776 0.776 0.587 2.5 0.453 0.454 0.454 0.265 1.25 0.369 0.341 0.355 0.166 0.625 0.230 0.250 0.240 0.051 0 0.184 0.194 0.189 -
數據處理：
-
貨期：3-5 working days
引用文獻
- CXCL4L1 May Help Differentiate Benign from Malignant Pulmonary Lesions and Predicts Prognosis of Patients with Lung Cancer L Zhang,Cancer management and research,2022
- Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy Zhang M, et al,Asian journal of andrology,2019
- Heparin-mimicking polyethersulfone Membranes-hemocompatibility, cytocompatibility, antifouling and antibacterial properties Shuang-Si Li. et al,Journal of Membrane Science,2016
- Nanofibrous Heparin and Heparin-mimicking Multilayers as Highly Effective Endothelialization and Antithrombogenic Coatings Nie C et al,Biomacromolecules,2015
產品評價
相關產品
靶點詳情
-
功能：Inhibitor of angiogenesis. Inhibitor of endothelial cell chemotaxis (in vitro).
-
基因功能參考文獻：
- Fibstatin and CXCL4L1 cooperate to inhibit endothelial cell proliferation, migration and tubulogenesis in vitro. PMID: 23747987
- fibstatin and CXCL4L1 have cooperative roles in inhibition of tumor invasion in lymph nodes PMID: 23747987
- Structural insight into the novel functional properties of human CXCL4L1. PMID: 23536183
- PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function PMID: 22384011
- both CXCR3A and CXCR3B are implicated in the chemotactic and vascular effects of CXCL4L1. PMID: 20980681
顯示更多
收起更多
-
亞細胞定位：Secreted.
-
蛋白家族：Intercrine alpha (chemokine CxC) family
-
數據庫鏈接：
Most popular with customers
-
Human Transforming Growth factor β1,TGF-β1 ELISA kit
Detect Range: 23.5 pg/ml-1500 pg/ml
Sensitivity: 5.8 pg/ml
-
-
-
Mouse Tumor necrosis factor α,TNF-α ELISA Kit
Detect Range: 7.8 pg/ml-500 pg/ml
Sensitivity: 1.95 pg/ml
-
-
-
-
